Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VOR-301
- Development stage
- Preclinical
- Lead developer
- Voro Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
VOR-301 is a tumor-activated immunocytokine in discovery-stage development by Voro Therapeutics for the treatment of solid tumors, including melanoma, renal cell carcinoma (RCC), ovarian cancer, and metastatic colorectal cancer (mCRC). Developed using Voro's proprietary PrimeBody™ platform, VOR-301 is designed to remain masked in healthy tissues and systemic circulation, selectively activating within the tumor microenvironment to provide sustained cytokine signaling while minimizing systemic toxicities.
Beyond the preview
Go deeper on VOR-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VOR-301.